Related Experiment Video
Updated: Jun 16, 2026
Using RNA-interference to Investigate the Innate Immune Response in Mouse Macrophages
Published on: November 3, 2014
mRNA-Laden Lipid-Nanoparticle-Enabled in Situ CAR-Macrophage Engineering for the Eradication of Multidrug-Resistant
Chunwei Tang1, Weiqiang Jing2, Kun Han1
1NMPA Key Laboratory for Technology Research and Evaluation of Drug Products and Key Laboratory of Chemical Biology (Ministry of Education), Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, 44 Cultural West Road, Jinan, Shandong Province 250012, China.
Abstract:
Sepsis, which is the most severe clinical manifestation of acute infection and has a mortality rate higher than that of cancer, represents a significant global public health burden. Persistent methicillin-resistant Staphylococcus aureus (MRSA) infection and further host immune paralysis are the leading causes of sepsis-associated death, but limited clinical interventions that target sepsis have failed to effectively restore immune homeostasis to enable complete eradication of MRSA. To restimulate anti-MRSA innate immunity, we developed CRV peptide-modified lipid nanoparticles (CRV/LNP-RNAs) for transient in situ programming of macrophages (MΦs). The CRV/LNP-RNAs enabled the delivery of MRSA-targeted chimeric antigen receptor (CAR) mRNA (SasA-CAR mRNA) and CASP11 (a key MRSA intracellular evasion target) siRNA to MΦs in situ, yielding CAR-MΦs with boosted bactericidal potency. Specifically, our results demonstrated that the engineered MΦs could efficiently phagocytose and digest MRSA intracellularly, preventing immune evasion by the "superbug" MRSA. Our findings highlight the potential of nanoparticle-enabled in vivo generation of CAR-MΦs as a therapeutic platform for multidrug-resistant (MDR) bacterial infections and should be confirmed in clinical trials.
Insights
Researchers developed nanoparticle-delivered RNA to reprogram macrophages, enhancing their ability to fight persistent methicillin-resistant Staphylococcus aureus (MRSA) infections and sepsis. This approach boosts innate immunity against the superbug.
Area of Science:
- Immunology
- Nanotechnology
- Infectious Diseases
Background:
- Sepsis, a severe infection complication, poses a significant global health threat with high mortality.
- Persistent methicillin-resistant Staphylococcus aureus (MRSA) and immune paralysis are major drivers of sepsis mortality.
- Current sepsis interventions struggle to restore immune balance and eradicate MRSA effectively.
Purpose of the Study:
- To develop a novel therapeutic strategy to restimulate anti-MRSA innate immunity.
- To engineer macrophages (MΦs) in situ for enhanced bactericidal activity against MRSA.
- To evaluate the efficacy of nanoparticle-mediated in vivo programming of MΦs.
Main Methods:
- Development of CRV peptide-modified lipid nanoparticles (CRV/LNP-RNAs) for transient in situ MΦ programming.
- Delivery of SasA-CAR mRNA and CASP11 siRNA to MΦs using CRV/LNP-RNAs.
- Generation of chimeric antigen receptor-engineered macrophages (CAR-MΦs) in situ.
Main Results:
- Engineered CAR-MΦs exhibited significantly boosted bactericidal potency against MRSA.
- The CAR-MΦs efficiently phagocytosed and digested intracellular MRSA, overcoming immune evasion.
- Demonstrated prevention of immune evasion by the multidrug-resistant (MDR) pathogen MRSA.
Conclusions:
- Nanoparticle-enabled in vivo generation of CAR-MΦs shows promise for treating MDR bacterial infections.
- This therapeutic platform offers a potential strategy to combat sepsis-associated MRSA.
- Further clinical trials are warranted to confirm the efficacy and safety of this approach.
More Related Videos
09:36Polyethyleneimine-coated Iron Oxide Nanoparticles as a Vehicle for the Delivery of Small Interfering RNA to Macrophages In Vitro and In Vivo
Published on: February 5, 2019
08:32Development and Assessment of Intracellular Infection Models for Staphylococcus aureus
Published on: January 17, 2025
